CTMSS

Single-Day Regimens for TMS: Recent Progress and Open Questions *Free Session*
2026-01-06 20:00 - 21:00 UTC
Kick off the year with complimentary Grand Rounds!
> >Register Now <<
Speaker: Jonathan Downar, MD, PhD, FRCPC
Improving access to TMS is a priority for practitioners and patients alike. Multi-day treatment protocols pose a significant logistical barrier to access for many patients, especially those in remote areas.
Recently, proof-of-concept studies have begun to investigate the effectiveness of single-day TMS regimens. Here we review the development of single-day TMS protocols, along with relevant studies on potential mechanisms. We consider new data on the outcomes of single-day TMS in various applications. We examine possible refinements of the approach to improve practicality, tolerability, and effectiveness. We consider important outstanding questions requiring future research on this novel but potentially quite impactful approach to TMS treatment.
Key learning objectives include:

Review rationale, mechanisms, and history of development of single-day TMS protocols.
Review recent progress in refining single-day TMS protocols and comparative outcomes vs. conventional once-daily protocols.
Review outstanding questions facing future developments and refinement of single-day TMS protocols.

Take advantage of our live Q&A session at the conclusion of the webinar.
*Registered attendees will receive access to the on-demand video recording by Friday, January 9, 2026. You will receive an email notification with instructions on accessing the video. You may register for the on-demand webinar any time after the live webinar.
When:
USA - January 6, 2026 at 8:00pm ET | 5:00pm PT
UK- January 7, 2026 at 1:00am GMT
Australia- January 7, 2026 at 12:00pm AEDT
Cost:
Member: FREE
Trainee Member: FREE
Non-Member: FREE
*CME not available for this session.
> >Register Now <<
About the Speaker

Jonathan Downar, MD, PhD, FRCPC
Dr Jonathan Downar is an Adjunct Professor in the Department of Psychiatry and Institute of Medical Science at the University of Toronto. He holds a clinical appointment at the Centre for Addiction and Mental Health in Toronto. He holds a PhD in functional neuroimaging from the University of Toronto, trained in medicine at the University of Calgary, and completed his psychiatry residency at the University of Toronto.
Dr Downar has published over 180 peer-reviewed articles on TMS and brain imaging, in journals including Lancet, JAMA Psychiatry, Nature Medicine, Nature Neuroscience, and Brain Stimulation. He is the senior author of the THREE-D study, a major Canadian TMS study published in Lancet in 2018 that demonstrated that TMS treatments could be reduced from 38 min sessions to 3 minute sessions with no loss of efficacy. He has also pioneered the use of novel TMS protocols including dorsomedial TMS and orbitofrontal TMS in depression and in other clinical disorders.
He is currently working to develop novel protocols that improve the practicality and economics of TMS, with the goal of achieving cost parity with pharmacotherapy and universal access to this powerful treatment.

TMS for Schizophrenia
2026-02-03 20:00 - 21:00 (Asia/Dubai)
> >Register Now <<
Speaker: Roscoe Brady, PhD, MD
In this presentation we will review the use of TMS for treating symptoms of schizophrenia as well as its use as a research tool to understand schizophrenia pathophysiology. We will discuss symptoms such as medication refractory hallucinations, negative symptoms, and cognitive dysfunction. We will review different approaches including targets derived from both structural and functional neuroanatomy. Finally, we will talk about future directions in treatment including the use of TMS for schizophrenia related comorbidity.
Key learning objectives include:

Summarize the history of TMS trials for medication resistant symptoms of schizophrenia.
Describe how TMS is used as a research tool for understanding schizophrenia pathology.
Describe future directions for TMS trials both for treating schizophrenia symptoms as well as schizophrenia related comorbidity.

One CME credit is available. CE Language
Take advantage of our live Q&A session at the conclusion of the webinar.
*Registered attendees will receive access to the on-demand video recording by Friday, February 6, 2026. You will receive an email notification with instructions on accessing the video. You may register for the on-demand webinar any time after the live webinar.
When:
USA - February 3, 2026 at 8:00pm ET | 5:00pm PT
UK- February 4, 2026 at 1:00am GMT
Australia- February 4, 2026 at 12:00pm AEDT
Cost:
Member: $25
Trainee Member: FREE
Non-Member: $50
> >Register Now <<
About the Speaker

Roscoe Brady
Roscoe Brady MD, PhD is a board-certified psychiatrist and neuroscientist. He is the Vice-Chair for Research in the Department of Psychiatry at Beth Israel Deaconess Medical Center and an Associate Professor at Harvard Medical School. He is also the director of the Research Concentration in the Beth Israel Deaconess Medical Center Harvard Psychiatry Residency Training Program. He is the recipient of the Jonathan F. Borus Outstanding Early Educator Award and Stuart T. Hauser Mentorship Award from Harvard Medical School. His research focus is developing neuromodulation treatments for medication resistant symptoms of psychotic disorders. He is the Principal Investigator of multiple NIMH R01 funded clinical trials.

Accelerated TMS for Depression: Does Imaging Matter?
2026-03-03 20:00 - 21:00 UTC
> >Register Now <<
Speaker: Joseph J. Taylor, MD, PhD
Neuroimaging is common in psychiatric research but rarely applied in psychiatric practice, even for brain stimulation treatments like transcranial magnetic stimulation (TMS). Recently, neuroimaging was used to target TMS during a condensed or “accelerated” treatment protocol. Known as Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT), this intervention resulted in rapid and substantial antidepressant benefits. However, it remains unclear if neuroimaging is necessary for the rapid and substantial antidepressant benefits of accelerated TMS. This question is important to answer because neuroimaging adds cost and complexity to TMS. Here, we will present data from the first head-to-head trial of accelerated TMS with and without imaging guidance for treatment-resistant depression.
Key learning objectives include:

Describe the development of accelerated TMS.
Outline the five ways that the Cole et al protocol (branded SAINT) differs from conventional iTMS.
Summarize the results of this trial comparing imaging-versus scalp-based targeting of accelerated TMS.

One CME credit is available. CE Language
Take advantage of our live Q&A session at the conclusion of the webinar.
*Registered attendees will receive access to the on-demand video recording by Friday, March 6, 2026. You will receive an email notification with instructions on accessing the video. You may register for the on-demand webinar any time after the live webinar.
When:
USA - March 3, 2026 at 8:00pm ET | 5:00pm PT
UK- March 4, 2026 at 1:00am GMT
Australia- March 4, 2026 at 12:00pm AEDT
Cost:
Member: $25
Trainee Member: FREE
Non-Member: $50
> >Register Now <<
About the Speaker

Joseph J. Taylor, MD, PhD
Dr. Taylor is an Assistant Professor of Psychiatry at Harvard Medical School. At Brigham and Women’s Hospital, he is the Medical Director of TMS and the Director of Clinical Trials in the Center for Brain Circuit Therapeutics, the Director of the Interventional Psychiatry Research Program, and the Associate Program Director and Research Track Co-Director of the Psychiatry Residency Program. Dr. Taylor’s has expertise in interventional psychiatry, an emerging subspecialty in which procedural treatments are used for psychiatric illnesses that have not improved with routine psychotherapy and medications. Most of his research focuses on deriving and testing brain circuit targets for brain stimulation or neurosurgical ablation. Throughout his career, Dr. Taylor has received funding from the Howard Hughes Medical Institute, the National institutes of Health, the Sidney R. Baer, Jr. Foundation, the Baszucki Group, the Brain and Behavioral Research Foundation, Mass General Brigham, and Harvard Medical School.

CTMSS Training Singapore: PULSES & Pain Academy
2026-03-07 - 2026-03-08

Marketing & Promotion of Off-Label Uses of Repetitive TMS Treatment (rTMS)
2026-04-07 20:00 - 21:00 UTC
> >Register Now <<
Speaker: Lindsay Oberman, PhD
This talk will review the Pro’s and Cons of off-label use of TMS. Dr. Oberman will then discuss the FDA clearance process and what indications are considered “off-label”. Finally, she will discuss the legal and ethical considerations for marketing and promoting off-label uses of TMS.
Key learning objectives include:

Gain awareness of what indications are "on label" versus "off label."
Gain awareness of federal regulations regarding marketing and promotion of FDA cleared devices.
Gain understanding of ethical considerations regarding marketing and use of rTMS off-label.

One CME credit is available. CE Language
Take advantage of our live Q&A session at the conclusion of the webinar.
*Registered attendees will receive access to the on-demand video recording by Friday, April 10, 2026. You will receive an email notification with instructions on accessing the video. You may register for the on-demand webinar any time after the live webinar.
When:
USA - April 7, 2026 at 8:00pm ET | 5:00pm PT
UK- April 8, 2026 at 1:00am BST
Australia- April 8, 2026 at 10:00am AEST
Cost:
Member: $25
Trainee Member: FREE
Non-Member: $50
> >Register Now <<
About the Speaker

Lindsay Oberman, PhD
Dr. Lindsay Oberman received her PhD from UCSD in Experimental Psychology in 2007. Since that time, she has published over 80 peer-reviewed articles. She has gained international attention for pioneering the use of Repetitive Transcranial Magnetic Stimulation (rTMS) in complex neurodevelopmental and neuropsychiatric disorders including autism, mood disorders, and traumatic brain injury. Dr. Oberman’s research involves the use of an experimental therapeutics approach applying neuroimaging and neurophysiological measures to identify dysfunctional neural circuitry associated with specific transdiagnostic behavioral domains such as mood regulation, sensory processing, social cognition, and executive functioning across disorders. In doing so, she is able to develop novel individualized rTMS treatment protocols that are informed by functional brain network organization. She is currently a Staff Scientist and Directs the Developmental Clinical Neurophysiology and Neurostimulation Research Program within the National Institute of Mental Health Intramural Research Program.

Combined Occipital and Trigeminal Afferent Stimulation for Depression: Findings from the Randomized Controlled Trial and the New ProLiv Home-Use Neuromodulation Device
2026-05-05 20:00 - 21:00 UTC
> >Register Now <<
Speaker: Linda Carpenter, MD
Earlier this year, the FDA approved a novel home-use device for treatment of major depressive disorder in patients who have not responded to antidepressant medication. Available only with a prescription, Proliv™Rx is a wearable, at-home neurostimulation headset that uses non-invasive electrical pulses to stimulate the occipital and trigeminal nerves through surface electrodes.
Dr. Carpenter was the lead Principal Investigator for the large randomized controlled trial that generated efficacy and safety data for this device. She will present the data and describe how the ProLiv device will be used in future clinical practice.
Key learning objectives include:

Evaluate the clinical trial data supporting efficacy and safety of a new home-use device for treatment of Major Depressive Disorder (MDD).
Describe external combined occipital and trigeminal stimulation as a novel mechanism of action in the field of therapeutic neuromodulation.
Discuss how the ProLiv Rx device is incorporated into clinical care as an adjunct therapy for MDD.

One CME credit is available. CE Language
Take advantage of our live Q&A session at the conclusion of the webinar.
*Registered attendees will receive access to the on-demand video recording by Friday, May 8, 2026. You will receive an email notification with instructions on accessing the video. You may register for the on-demand webinar any time after the live webinar.
When:
USA - May 5, 2026 at 8:00pm ET | 5:00pm PT
UK- May 6, 2026 at 1:00am BST
Australia- May 6, 2026 at 10:00am AEST
Cost:
Member: $25
Trainee Member: FREE
Non-Member: $50
> >Register Now <<
About the Speaker

Linda Carpenter, MD
Dr. Carpenter has had nearly three decades of externally funded research focused on understanding biomarkers of early life stress and developing new treatments. She has expertise in clinical trials research involving pharmacotherapy and device-based neuromodulation treatments and has been PI on multiple industry- and NIH-funded randomized clinical trials, evaluating the safety and efficacy of both drug- and device-based therapies for depression and anxiety disorders. She has also conducted studies examining various mechanisms of therapeutic action and biomarkers of risk for psychiatric disorders.
For the past two decades, Dr. Carpenter's primary research focus has included therapeutic brain stimulation, and she has led numerous studies examining the efficacy, safety, and mechanisms of VNS, DBS, tDCS, TMS, and other neuromodulation devices in clinical populations.
Dr. Carpenter recently led the multi-center investigation of Proliv, a novel, FDA-cleared home-use device that delivers electrical trigeminal/occipital nerve stimulation for depression, and she is lead PI for a trial that uses fMRI-EEG-based neurofeedback for self-neuromodulation of a targeted depression circuit.
For the past 5 years Dr. Carpenter has also been developing methods for sustaining TMS antidepressant response over time with maintenance treatment and ecological momentary assessment.
Dr. Carpenter is the current Director of the CTMSS’s PULSES training course, and she serves on multiple other CTMSS committees.

PULSES Boston
2026-06-03 - 2026-06-04
Course Overview
This in-depth training course offers a Certificate of Completion and features lectures and over 3 hours of hands-on training delivered by Clinical TMS Society renowned clinicians, engineers, and researchers, along with special guests. Attendees will receive current, historical, and practical knowledge for treating patients with TMS based on the best available evidence.
The Program Includes:

A review of the clinical studies that serve as the foundation for treatment of TMS for depression, as well as clinically applicable research and current important studies.
Four lectures on the practical administration of TMS for patients, including practice setup to patient dosing, scheduling, and management.
A review of protocols for TMS: high frequency, theta-burst, low frequency, bilateral, alternative brain targets, rescue treatment, and maintenance treatment.
A revised lecture on TMS risks and their prevention and management, including seizure protocol review.
Hands-on training on coil location placement & motor threshold determination with multiple TMS devices.
A review of promising indications beyond depression, including, obsessive compulsive disorder, smoking cessation, migraine, post-traumatic stress disorder, anxiety, and pain.
An extended Q&A Panel with all PULSES faculty and special guests.

MORE DETAILS COMING SOON... Sign up for updates on when CTMSS opens PULSES registration...

Pain Academy Boston
2026-06-04

CTMSS 14th Annual Meeting
2026-06-04 - 2026-06-06

Clinical Outcomes Comparing MST and ECT in Patients with Depression
2026-07-07 20:00 - 21:00 UTC
> >Register Now <<
Speaker: Daniel M. Blumberger, MD, MSc, FRCPC, FCTMSS
This presentation will present data from a large confirmatory efficacy trial of Magnetic Seizure Therapy in unipolar Depression and a smaller trial in patients with Bipolar Depression.
This treatment utilizes transcranial magnetic stimulation to induce a brief seizure with the hope of inducing similar clinical benefit without cognitive adverse effects of ECT.
Key learning objectives include:

Review the background and rationale for studying MST and ECT in the treatment of depression.
Understand the methodology and design of the CREST and CORRECT-BD trials.
Evaluate the efficacy, safety, tolerability, and clinical implications of MST as a potential treatment for TRD.

One CME credit is available. CE Language
Take advantage of our live Q&A session at the conclusion of the webinar.
*Registered attendees will receive access to the on-demand video recording by Friday, July 10, 2026. You will receive an email notification with instructions on accessing the video. You may register for the on-demand webinar any time after the live webinar.
When:
USA - July 7, 2026 at 8:00pm ET | 5:00pm PT
UK- July 8, 2026 at 1:00am BST
Australia- July 8, 2026 at 10:00am AEST
Cost:
Member: $25
Trainee Member: FREE
Non-Member: $50
> >Register Now <<
About the Speaker

Daniel M. Blumberger, MD, MSc, FRCPC, FCTMSS

Dr. Blumberger is a Senior Scientist in the Campbell Family Mental Health Research Institute at Centre for Addiction and Mental Health and a subspecialist in geriatric psychiatry. He is the Temerty Chair in Therapeutic Brain Intervention and the Scientific Director of the Temerty Centre for Therapeutic Brain Intervention. He is the Chief of the General Adult Psychiatry and Health Systems Division at CAMH and is a Professor in the Department of Psychiatry at the University of Toronto. He is the Provincial Clinical Lead for Neurostimulation Procedure for Ontario Health.
His primary area of research focuses on clinical intervention trials of neurostimulation and other novel treatments for depression across the lifespan.
He is the principal or co-investigator on multiple clinical trials using different interventional psychiatry modalities including: psilocybin assisted psychotherapy, IV ketamine, electroconvulsive therapy (ECT), magnetic seizure therapy (MST), repetitive transcranial magnetic stimulation (rTMS) and transcranial direct current stimulation (tDCS).

Pain Academy San Diego
2026-10-15

PULSES Providence
2026-10-23 - 2026-10-25
Course Overview
This in-depth training course offers a Certificate of Completion and features lectures and over 3 hours of hands-on training delivered by Clinical TMS Society renowned clinicians, engineers, and researchers, along with special guests. Attendees will receive current, historical, and practical knowledge for treating patients with TMS based on the best available evidence.
The Program Includes:

A review of the clinical studies that serve as the foundation for treatment of TMS for depression, as well as clinically applicable research and current important studies.
Four lectures on the practical administration of TMS for patients, including practice setup to patient dosing, scheduling, and management.
A review of protocols for TMS: high frequency, theta-burst, low frequency, bilateral, alternative brain targets, rescue treatment, and maintenance treatment.
A revised lecture on TMS risks and their prevention and management, including seizure protocol review.
Hands-on training on coil location placement & motor threshold determination with multiple TMS devices.
A review of promising indications beyond depression, including, obsessive compulsive disorder, smoking cessation, migraine, post-traumatic stress disorder, anxiety, and pain.
An extended Q&A Panel with all PULSES faculty and special guests.

Register
